Scarica l'app Stockscreener
0.00
100.00%
-5.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TSVT Giù?
Forum
Previsione
Precedente Chiudi:
$5.00
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$266.14M
Reddito:
$44.12M
Utile/perdita netta:
$-156.25M
Rapporto P/E:
0.00
EPS:
-3.07
Flusso di cassa netto:
$-154.61M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
Nome
2 Seventy Bio Inc
Settore
Industria
Telefono
339-499-9300
Indirizzo
60 BINNEY STREET, CAMBRIDGE
Confronta TSVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
0.00 | 266.14M | 44.12M | -156.25M | -154.61M | -3.07 |
|
ONC
Beigene Ltd Adr
|
236.54 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.34 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.97 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.54 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-06 | Downgrade | Goldman | Neutral → Sell |
| 2024-01-31 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-01-31 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-13 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-05-02 | Iniziato | Goldman | Buy |
| 2022-02-10 | Iniziato | SVB Leerink | Outperform |
| 2022-01-06 | Iniziato | Cowen | Outperform |
| 2021-11-09 | Iniziato | Canaccord Genuity | Buy |
| 2021-11-08 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
2 Seventy Bio Inc Borsa (TSVT) Ultime notizie
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Earnings call transcript: Nuvation Bio Q1 2025 sees strategic focus amid EPS miss - Investing.com India
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $5.60 - Defense World
Neuroscientific to Acquire Leading Stem Cell Technology - Investing News Network
American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Intech Investment Management LLC - The AM Reporter
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
TSVT Up on Acquisition Agreement With BMY for $286 Million - Yahoo Finance
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
2 Seventy Bio Inc Azioni (TSVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2 Seventy Bio Inc Azioni (TSVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baird William D III | President and CEO |
Mar 17 '25 |
Sale |
4.95 |
5,092 |
25,180 |
1,121,034 |
| Eatwell Victoria | Chief Financial Officer |
Mar 17 '25 |
Sale |
4.95 |
2,592 |
12,817 |
444,387 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
11,095,936 |
54,702,964 |
0 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
5,142,111 |
25,350,607 |
0 |
| Snow Jessica | See Remarks |
Jan 06 '25 |
Sale |
2.79 |
5,114 |
14,289 |
147,365 |
| Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
| Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
| Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
| Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
| Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
1.55%
3.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):